Ocular Therapeutix™ Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Post-Surgical Ocular Inflammation and Pain
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the enrollment of the first patients in a third Phase 3 clinical trial for DEXTENZATM (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of post-surgical ocular inflammation and pain. Based on the results of the Company’s two previously c
